Abstract: Provided is a process for producing (3R)-2?-(4-bromo-2-fluorobenzyl)spiro{pyrrolidine-3,4?(1?H)-pyrrolo[1,2-a]pyrazine}-1?,2,3?,5(2?H)-tetraone (compound A). The method includes converting an optically active succinimide derivative of formula (I) to compound A, in which the compound of formula (I) has been prepared by reacting a base with an optically active amide derivative of formula (VI).

Abstract: A process for producing optically active succinimide derivatives as key intermediates of (3R)-2?-(4-bromo-2-fluorobenzyl)spiro{pyrrolidine-3,4?(1?H)-pyrrolo[1,2-a]pyrazine}-1?,2,3?,5(2?H)-tetraone, which comprises the following reaction steps.

Abstract: A process for producing optically active succinimide derivatives as key intermediates of (3R)-2?-(4-bromo-2-fluorobenzyl)spiro{pyrrolidine-3,4?(1?H)-pyrrolo[1,2-a]pyrazine}-1?,2,3?,5(2?H)-tetraone, which comprises the following reaction steps.

Abstract: A process for producing optically active succinimide derivatives as key intermediates of (3R)-2?-(4-bromo-2-fluorobenzyl)spiro{pyrrolidine-3,4?(1H)-pyrrolo[1,2-a]pyrazine}-1?,2,3?,5(2?H)-tetraone, which comprises the following reaction steps.

Abstract: Provided is a process for efficiently producing N-glycyltyrosine of high purity represented by the following formula: a salt thereof, or a solvate thereof, which comprises adding dropwise to an aqueous suspension of tyrosine or a salt thereof 2 equivalents or more of a haloacetyl halide and an aqueous solution of an inorganic base simultaneously in the presence or absence of an organic solvent, and subjecting the resulting N-haloacetyltyrosine to a reaction with an ammonium ion. Also provided are N-glycyl-L-tyrosine dehydrate having the crystal structures showing specific diffraction patterns in X-ray powder diffraction and processes for producing the same which are characterized by comprising crystallizing the dihydrate from an ethanol-water mixed solvent or water.

Abstract: The present invention relates to propenone derivatives represented by the following formula (I): ##STR1## wherein R.sup.1 represents hydrogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl, or YR.sup.5 (wherein Y represents S or O; and R.sup.5 represents substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or a substituted or unsubstituted cyclic ether residue); R.sup.2 and R.sup.3 independently represent hydrogen, lower alkyl, or substituted or unsubstituted aralkyl, or alternatively R.sup.2 and R.sup.3 are combined to form substituted or unsubstituted methylene or ethylene; R.sup.4 represents hydrogen, hydroxy, lower alkyl, substituted or unsubstituted aralkyl, lower alkoxy, substituted or unsubstituted aralkyloxy, or halogen; and X represents substituted or unsubstituted indolyl; or pharmaceutically acceptable salts thereof.

Abstract: N-chloroacetylglutamine is produced by reacting chloroacetyl chloride with an alkaline aqueous solution of glutamine the presence of a water-immiscible organic solvent, separating an aqueous layer by liquid-liquid separation, and crystallizing N-chloroacetyl-glutamine from the aqueous layer under acidic conditions. N-Chloroacetyl-glutamine useful as an intermediate for producing glycyl-L-glutamine which has higher stability than L-glutamine and is used as a component of an infusion solution can be obtained with high efficiency at low cost.

Abstract: The present invention relates to glutathione monoester sulfonate represented by formula (I): ##STR1## (wherein R.sup.1 represent lower alkyl, and R.sup.2 represents lower alkyl, or substituted or unsubstituted aryl) which readily crystallizes and has high stability, and a simple process for producing the same. According to the process, the product having high purity can be obtained in high yields.

Abstract: In the formulae, R.sup.1, R.sup.2, and R.sup.3 independently represent lower alkyl or aryl, and R.sup.4 represents lower alkyl.The present invention relates to a process for producing an indolocarbazole derivative represented by Formula (II), comprising the acidic treatment of a silylated indolocarbazole derivative represented by Formula (VI).

Abstract: Disclosed is a process for producing alanylglutamine, which comprises reacting an N-(2-substituted)-propionylglutamine compound represented by the formula (I): ##STR1## where X represents halogen, alkylsulfonyloxy, or substituted or unsubstituted arylsulfonyloxy, with ammonia at a temperature of 60.degree. C. or below.in accordance with the present invention, highly purified alanylglutamine can be produced in a high yield, without racemization.

Abstract: 5-Aminoflavone derivatives represented by the formula (I): ##STR1## wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are the same or different and represent hydrogen, substituted or unsubstituted lower alkyl, lower alkenyl, halogen-substituted or unsubstituted lower alkanoyl or lower alkoxycarbonyl, X.sup.1, X.sup.2, Y.sup.1 and Y.sup.2 are the same or different and represent hydrogen, halogen or lower alkyl, at least one of X.sup.1 and X.sup.2 represents halogen or lower alkyl, X.sup.3 represents hydrogen, substituted or unsubstituted lower alkyl, lower alkenyl, lower alkynyl, halogen, hydroxy, substituted or unsubstituted lower alkoxy, NR.sup.5 R.sup.6 (wherein R.sup.5 and R.sup.6 are the same or different and represent hydrogen, or substituted or unsubstituted lower alkyl, or R.sup.5 and R.sup.

Abstract: The present invention relates to N-acylglutamine derivatives of formula (I): ##STR1## The N-acylglutamine derivatives are well compatible with oily bases and have good skin-moisturizing activity and hair growth-stimulative effect. These are useful as cosmetics and hair growth stimulants.

Abstract: Disclosed is a process for producing alanylglutamine, which comprises reacting an N-(2-substituted)-propionylglutamine compound represented by the formula (I): ##STR1## where X represents halogen, alkylsulfonyloxy, or substituted or unsubstituted arylsulfonyloxy, with ammonia at a temperature of 60.degree. C. or below.In accordance with the present invention, highly purified alanylglutamine can be produced in a high yield, without racemization.

Abstract: An indole derivative represented by formula (I): ##STR1## wherein R.sup.1 is a lower alkoxymethyl group or a formyl group, R.sup.2 is a lower alkyl group, R.sup.3 is a hydrogen atom or a lower alkyl group and R.sup.4 is a hydrogen atom or a lower alkyl group, which is useful as an intermediate for the synthesis of a compound, 5-aziridino-3-hydroxymethyl-l-methyl-2- (1H-indole-4,7-dione)prop-.beta.-ene-.alpha.-ol, which has antitumor activity.

Abstract: Novel mitomycin derivatives represented by the formula (I) are obtained by introducing a substituent at the 6-position. The mitomycin derivatives of the present invention have an antitumor activity.

Abstract: Novel mitomycin derivatives represented by the formula (I) are obtained by introducing a substituent at the 6-position. The mitomycin derivatives of the present invention have an antitumor activity.

Abstract: Disclosed is pyrazoloacridone derivatives represented by formula (I): ##STR1## wherein: each of R.sup.1a, R.sup.1b, R.sup.1c and R.sup.1d independently represents hydrogen, lower alkyl, --(CH.sub.2).sub.p --Xwherein p represents an integer of 1 to 6, and X represents hydroxy, lower alkoxy or --NR.sup.2a R.sup.2bwherein each of R.sup.2a and R.sup.2b independently represents hydrogen, lower alkyl, or --(CH.sub.2).sub.m --Ywherein m represents an integer of 1 to 6, and Y represents hydroxy, lower alkoxy or --NR.sup.3a R.sup.3bwherein each of R.sup.3a and R.sup.3b independently represents hydrogen or lower alkylor --CH[(CH.sub.2).sub.n OH].sub.2wherein n represents an integer of 1 to 5; or a pharmaceutically acceptable salt thereof.

Abstract: Disclosed are mitomycin derivatives of formula (I): ##STR1## where W represents halogen; X represents methoxy, amino or ethylenimino; Y represents hydrogen or methyl; Z represents hydrogen or methyl; and one of R.sup.1 and R.sup.2 represents carbamoyloxymethyl, and the other represents hydrogen. The derivatives are usable as an antitumor and antibacterial agent.

Abstract: Disclosed in a mitomycin derivative represented by the formula (I): ##STR1## wherein W is a heterocyclic group.

Abstract: Novel DC-89 compounds represented by the general formula: ##STR1## wherein X represents a single bond or --CH.sub.2 --; and when X represents a single bond, Y represents --CH.sub.2 Br or --CH.sub.2 Cl and when X represents --CH.sub.2 --, Y represents Br, are obtained by the present invention. The compounds have antibacterial and anti-tumor activity.